Replies to post #214071 on NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Thanks Lykiri.
Looks like nearly all received Bev.
And it looks, in my opinion, that Keytruda did nothing as a post-surgery adjuvant, but did something as a pre-surgery neo-adjuvant.
Bear in mind that only approx 25% of rGBM patients are deemed suitable candidates for repeat surgery.
And repeat surgery affords improved survival in any event.

Eight observational studies reporting prognostic HRs in 10 cohorts were included. They described 1906 recurrent GBM diagnoses, managed by surgery at primary diagnosis, with 709 (37%) undergoing further repeat surgery at recurrence. Repeat surgery was shown to confer a statistically significant survival advantage compared with no surgery at recurrence in the pooled cohort (HR, 0.722; P < 0.001). Newer studies trended toward a more superior prognostic advantage of repeat surgery compared with earlier studies (effect coefficient, 0.856; P = 0.012).

https://www.ncbi.nlm.nih.gov/pubmed/29654958